Entering text into the input field will update the search result below

Cellectis shares dip on pricing follow-on offering at $2.50/ADS

Feb. 03, 2023 5:46 AM ETCellectis S.A. (CLLS)By: Niloofer Shaikh, SA News Editor1 Comment
  • Cellectis S.A. (NASDAQ:CLLS) has priced its previously announced $22M underwritten global offering by way of a capital increase of 8.8M American Depositary Shares at $2.50/ADS.
  • Each ADS represents the right to receive one ordinary share of Cellectis, nominal value €0.05 per share, comprised

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

lshiang profile picture
The company is quite stupid to make equity offering at such a low price. Why can't the management team plan ahead when stock price was around $10? The odds to survive is probably slim, if not none.

About CLLS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Cellectis S.A.
Innate Pharma S.A.
Harpoon Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
Mesoblast Limited
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.